# OMX Ventures

> OMX Ventures is a VC fund in Boston backing Biotechnology and Therapeutics. See 25 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Boston, United States
- Total investments: 25
- Last investment: Apr 2026
- Lead investor: 48%
- Fund size: $250M
- Last fund: Feb 2022
- Last updated: Aug 2026
- Website: https://www.omx.vc/

OMX Ventures is a VC fund in Boston focused on Biotechnology and Therapeutics. OMX Ventures is investing at the convergence of biology and computing.

## Contacts

5 contacts available for OMX Ventures. Shizune tracks 4 team members at OMX Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/omx-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 18 | 72% |
| Therapeutics | 6 | 24% |
| Medical | 4 | 16% |
| Health Care | 4 | 16% |
| Life Science | 4 | 16% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 11 | 44% |
| Series A | 8 | 32% |
| Series B | 3 | 12% |
| Pre-Seed | 1 | 4% |
| Series D | 1 | 4% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 15 | 60% |
| United Kingdom | 3 | 12% |
| Belgium | 1 | 4% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Daniel Fero | Managing Director & Co-Founder | 5 | — |
| Nick Haft | Managing Director & Co-Founder | 5 | — |
| Craig Asher | Managing Director & Co-Founder | 4 | — |
| Jamie Kasuboski | Vice President | 1 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Lightcast Discovery | Lightcast uses a microfluidic platform to make advances towards unique clinical approaches, new therapies, and innovative products.The company's mission is to push the boundaries of complex cell analysis. Using the Lightcast platform, the company is working with major pharmaceutical companies and leading academic institutes to enable them todiscover more. The Lightcast platform allows precise and highly flexible independent control of thousands of droplets. By combining droplets containing different cells, reporters or other reagents we can perform complex workflows without the need to manipulate cells by hand.Lightcast Discovery was founded in 2019 by Cameron Frayling. | $27M | Venture - Series Unknown | Apr 14, 2026 |  |
| Syndex Bio | Syndex Bio is a biotechnology platform offering molecular technologies and AI for the diagnosis and treatment of disease. | $15.5M | Seed | Feb 23, 2026 |  |
| MRM Health NV | MRM Health NV, is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome. MRM Health was incorporated early 2020 by MRM Technologies, a Center of Expertise for microbiome research based in the biotech cluster in Ghent, in a joint venture with the Flemish Institute ofBiotechnology (VIB), an excellence-based entrepreneurial life sciences research institute in Flanders, Belgium, that focuses on translating basic scientific results into pharmaceutical, agricultural and industrial applications. | $64.1M | Series B | Sep 04, 2025 |  |
| Matterworks | Matterworks accelerates the discovery and engineering through faster and more comprehensive metabolomic screening. |  | Series A | Jun 03, 2025 |  |
| Constructive Bio | Constructive is a ground-breaking method for creating wholly artificial genomes and rewriting the genetic code of living things. | $57.7M | Series A | Sep 24, 2024 |  |
| OverT Bio | OverT Bio operates as a biotech company that provide cell therapy for cancers.. The company's cell therapies identify and develop novel genetic modifications that will help immune cells overcome barriers created by tumors and lead to effective and durable immunotherapies, helping the healthcare industry to identify and cure cancer. | $16M | Seed | May 06, 2024 |  |
| Tagomics | Tagomics transform disease diagnosis through comprehensive multitopic profiling. | $8.5M | Seed | Feb 21, 2024 |  |
| Freya Biosciences | Freya Biosciences is a clinical-stage women’s health company pioneering a new class of microbial immunotherapies. It is based in Copenhagen and Boston. | $38M | Series A | Dec 12, 2023 |  |
| Aperiam Bio | Aperiam Bio partners with enzyme engineers and distributors to create and share stabilized, solubilized, and catalytically optimized proteins. The company was founded in 2021 and is headquartered in Austin, Texas, United States. | $9M | Seed | Nov 29, 2023 |  |
| VedaBio | VedaBio innovative platform for near-instant molecular detection of multiplexed analytes delivers best-in-class accuracy without the requirement for target amplification transforming molecular biology. | $40M | Series A | Oct 17, 2023 |  |

10 of 25 investments shown.

## Co-investors
- [Artis Ventures](https://shizune.co/investors/profile/artis) — VC Fund, 6 deals together
- [Axial VC](https://shizune.co/investors/profile/axial-vc) — VC Fund, 5 deals together
- [Civilization Ventures](https://shizune.co/investors/profile/civilization-ventures) — VC Fund, 4 deals together
- [+ND Capital](https://shizune.co/investors/profile/nd-capital) — VC Fund, 4 deals together
- [Presight Capital](https://shizune.co/investors/profile/presight-capital) — VC Fund, 4 deals together
- [Ahren Innovation Capital](https://shizune.co/investors/profile/ahren-innovation-capital) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does OMX Ventures invest in?

OMX Ventures invests primarily in Biotechnology, Therapeutics and Medical startups, most often at Seed and Series A stage. Most of the 25 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact OMX Ventures?

Public channels for OMX Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at OMX Ventures?

The team at OMX Ventures includes Daniel Fero (Managing Director & Co-Founder), Nick Haft (Managing Director & Co-Founder) and Craig Asher (Managing Director & Co-Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co